Wedbush Starts Lexicon Pharmaceuticals (LXRX) at Outperform; Multiple Shots on Goal Reduces Pipeline Risk
Tweet Send to a Friend
Wedbush initiates coverage on Lexicon Pharmaceuticals (NASDAQ: LXRX) with an Outperform rating. PT $3.
Wedbush analyst says, "The company has ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wedbush analyst says, "The company has ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
